Skip to content
Clinical Trials – home
LatviaBack to Latvia

Clinical trials in Jelgava – page 17

210 clinical trials in Jelgava, Latvia. Every trial is listed in the EU Clinical Trials Register and updated daily.

LatviaOur site in LatviaKliniskiePetijumi.lv(opens in a new tab)
Jelgava at a glance
210
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

210 trials in Jelgava

Open in trial search

Study on Seralutinib for Treating Pulmonary Arterial Hypertension in Patients

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Seralutinib
  • Sponsor:GB002 Inc.

Colitis ulcerative

Not recruiting

Study on Long-Term Safety and Effectiveness of Upadacitinib for Patients with Ulcerative Colitis

Investigational
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Upadacitinib
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Embolism

Not recruiting

Study on REGN9933 for Preventing Blood Clots in Adults After Knee Replacement Surgery

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Regeneron Pharmaceuticals Inc.

Partial seizures

Not recruiting

Study on the Effects of Azetukalner in Reducing Focal-Onset Seizures for Patients with Epilepsy

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Azetukalner
  • Sponsor:Xenon Pharmaceuticals Inc.

Study on the Effects of Tildacerfont and Hydrocortisone in Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Spruce Biosciences Inc.

Study on Tildacerfont to Reduce Glucocorticoid Use in Adults with Classic Congenital Adrenal Hyperplasia

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:Spruce Biosciences Inc.

Study on Darolutamide and Androgen Deprivation Therapy for Men with Metastatic Hormone-Sensitive Prostate Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Bladder cancer

Not recruiting

Study of Pembrolizumab with Chemoradiotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study on Milvexian for Preventing Stroke in Patients with Acute Ischemic Stroke or High-Risk Transient Ischemic Attack

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

COVID-19

Not recruiting

Study on the Effectiveness and Safety of Bemnifosbuvir for High-Risk COVID-19 Patients

Registered drug
Countries:LatviaLatvia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nirmatrelvir
  • Sponsor:Atea Pharmaceuticals Inc.

Study on Milvexian and Drug Combination for Patients Recovering from a Heart Attack

Registered drug
Countries:LatviaLatvia
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Janssen Cilag International

Other cities in Latvia

The busiest research cities in the country

All 18 cities in Latvia

Clinical research in Jelgava

What the registry says about research in the country

01 Diabetes Management Studies

Clinical investigations focusing on type 2 diabetes management through combination therapy approaches. Research evaluates the effectiveness of gliclazide MR when combined with existing treatments.

  • Treatment Optimization
  • Glycemic Control
  • Combination Therapy

Studies aim to improve blood sugar control in patients not achieving optimal results with current medications.

02 Diabetic Eye Disease Research

Groundbreaking research examining the impact of semaglutide on diabetic retinopathy in patients with type 2 diabetes. This long-term safety study evaluates treatment effects on eye health.

  • Retinopathy Development
  • Disease Progression
  • Ophthalmologic Assessment

The research includes standardized ophthalmic evaluations to monitor disease progression and treatment outcomes.

03 Therapeutic Safety Studies

Post-authorization safety assessments conducted under European Medicines Agency oversight, focusing on long-term effects of diabetes treatments.

  • Safety Monitoring
  • Long-term Outcomes
  • Treatment Effects

These studies contribute to understanding the complete safety profile of new diabetes medications.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.